Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Skin and subcutaneous tissue disorders – page 58

  • 844 clinical trials
  • 268 recruiting
  • 353 conditions
  • 25 countries

Conditions in this area

353 conditions with trials, the busiest first

Dermatitis atopic88Malignant melanoma79Systemic lupus erythematosus61Psoriasis53Hidradenitis47Psoriatic arthropathy46Systemic scleroderma39Metastatic malignant melanoma32Vitiligo23Hereditary angioedema22Chronic spontaneous urticaria19Malignant melanoma stage III17Dermatomyositis15Non-small cell lung cancer15Alopecia areata14Cutaneous lupus erythematosus14Rheumatoid arthritis14Diabetic foot13Basal cell carcinoma12Malignant melanoma stage IV12Actinic keratosis11Hepatocellular carcinoma11Neurodermatitis11Squamous cell carcinoma of skin11+329

Clinical trials in Skin and subcutaneous tissue disorders

844 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

844 clinical trials

Hidradenitis

Not recruiting

Study on the Long-Term Safety of Povorcitinib for Patients with Moderate to Severe Hidradenitis Suppurativa

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:4-[3-(Cyanomethyl)-3-(3',5'-Dimethyl-1H,1'H-[4,4'-Bipyrazol]-1-Yl)Azetidin-1-Yl]-2,5-Difluoro-N-[(2S)-1,1,1-Trifluoropropan-2-Yl]Benzamide
  • Sponsor:Incyte Corp.

Neurofibromatosis+1

Not recruiting

Study on Selumetinib for Adults with Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Selumetinib
  • Sponsor:AstraZeneca AB

Radiation skin injury

Not recruiting

Study on GR1014 Gel to Prevent Skin Damage from Radiation in Breast Cancer Patients After Lumpectomy

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Amifostine Thiol
  • Sponsor:Graegis Pharmaceuticals Limited

Systemic lupus erythematosus+1

Not recruiting

Study on the Safety and Effects of YTB323, Fludarabine Phosphate, and Tocilizumab in Patients with Severe, Refractory Systemic Lupus Erythematosus

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Novartis Pharma AG

Oesophageal carcinoma+3

Not recruiting

Study on PET Tracers [18F]F-AraG and [89Zr]Zr-Df-Crefmirlimab for Evaluating T Cell Activation in Non-Small Cell Lung Cancer Patients

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Nelarabine
  • Sponsor:Amsterdam UMC Stichting

Malignant melanoma+4

Not recruiting

Study on the Effectiveness and Safety of RO7198457 and Pembrolizumab for Patients with Untreated Advanced Melanoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Autogene Cevumeran
  • Sponsor:Genentech Inc.

Squamous cell carcinoma of skin

Not recruiting

Study of mRNA-4157 and Pembrolizumab for Patients with Resectable Locally Advanced Cutaneous Squamous Cell Carcinoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Mrna-4157
  • Sponsor:Merck Sharp & Dohme LLC

Dermatitis atopic

Not recruiting

Study on Amlitelimab for Patients Aged 12 and Older with Moderate to Severe Atopic Dermatitis Using Topical Corticosteroids and Inadequate Response to Previous Treatments

Registered drug
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Amlitelimab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Gastrointestinal melanoma+7

Not recruiting

Study of Encorafenib, Binimetinib, and Pembrolizumab for Patients with Advanced Melanoma with BRAF V600E/K Mutation

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Binimetinib
  • Sponsor:Pfizer Inc.

Chronic cutaneous lupus erythematosus

Not recruiting

Study of daxdilimab injection for adults with moderate to severe discoid lupus erythematosus

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Daxdilimab
  • Sponsor:Horizon Therapeutics Ireland Designated Activity Company

Psoriatic arthropathy

Not recruiting

Study on Tildrakizumab for Patients with Active Psoriatic Arthritis Who Have Previously Used Anti-TNF Therapy

Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Tildrakizumab
  • Sponsor:Sun Pharmaceutical Industries Limited

Hidradenitis

Not recruiting

Study on Long-Term Use of Spesolimab for Patients with Hidradenitis Suppurativa Who Completed a Previous Spesolimab Study

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Spesolimab
  • Sponsor:Boehringer Ingelheim Espana S.A.

Substances studied in this area

The therapies tested most often in Skin and subcutaneous tissue disorders trials.

Pembrolizumab57 clinical trialsNivolumab33 clinical trialsSodium Chloride22 clinical trialsDeucravacitinib19 clinical trialsCemiplimab18 clinical trialsUpadacitinib17 clinical trialsIpilimumab15 clinical trialsRituximab13 clinical trialsCyclophosphamide12 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.